Cholesterol and coronary heart disease: Screening and treatment

Quality in Health Care

Volumn 7, Issue 4, 1998, Pages 232-239

  Ebrahim, Shah ^a,b,c   Davey Smith, George ^b,c   McCabe, Chris ^d   Payne, Nick ^d   Pickin, Mark ^d   Sheldon, Trevor A ^e   Lampe, Fiona ^a   Sampson, Fiona ^d   Ward, Sue ^d   Wannamthee, Goya ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b Department of Clinical Epidemiology ^*  (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINE; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; DIETARY INTAKE; DRUG COST; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; META ANALYSIS; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION;

EID: 3142530254     PISSN: 09638172     EISSN: None     Source Type: Journal    
DOI: 10.1136/qshc.7.4.232     Document Type: Article

References (76)

1. Mortality statistics: cause, 1995. London: The Stationery Office, 1997. (Series DH2;22.)
2. Office of Health Economics Coronary heart disease. The needs for action. London: OHE, 1990.
3. University of Leeds and University of York. Cholesterol: screening and treatment Effective Health Care 1993;1(3): 1-8
4. Sheldon TA, Song F, Davey Smith G, et al. Cholesterol screening and cholesterol lowering treatment. Quality in Health Care 1993;2:134-7.
5. Com M-C, Guralnik JM, Salive ME, et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med 1997;126:753-60.
6. Jacobs DR,1 Herberr B, Schreiner PJ, et al. Reduced cholesterol is associated with recent minor illness. The CARDIA study. Am J Epidemiol 1997;146:558-64.
7. Iribarren C, Jacobs DR, Sidney S, et al. Serum total cholesterol and risk of hospitalisation, and death from respiratory disease. Int J Epidemiol 1997;26:1191-202.
8. Davey Smith G, Shipley MJ, Marmot MGM, et al. Plasma cholesterol concentrations and mortality in the Whitehall study. JAMA 1992;267:70-6.
9. Grundy SM, Bilheimer D, Blackburn H, et al. Rationale of the diet-heart statement of the American Heart Association: report of the Nutrition Committee. Circulation 1982;65:839A-854A.
10. Clarke R, Frost C, Collins R, et al. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. BMJ 1997;314.112-7.
11. Shaper AG, Pocock SJ, Phillips AN, et al. A scoring system to identify men at high risk of heart attack Health Trends 1987;19:37-9
12. Naylor CD, Basinski A, Frank JW, et al. Asymptomatic hypercholesterolaemia: a clinical policy review. J Clin Epidemiol 1990;43:1046-60.
13. Packard CJ, Bell MA, Eaton RH, et al. A pilot scheme for improving the accuracy of serum cholesterol measurement in Scotland and Northern Ireland. Ann Clin Biochem 1993; 30:387-93.
14. Jones A, Davies DH, Dove JR, et al. Identification and treatment of risk factors for coronary heart disease in general practice: a possible screening model BMJ 1988;296:1711-4
15. Miller WG, McKenney JM, Conner MR, et al. Total error assessment of five methods for cholesterol screening, Clin Chem 1993;39:297-304.
16. Majeed A, Hilton S. Home cholesterol testing [letter]. Lancet 1993;341 314
17. Hilton S, Rink E, Fletcher J, et al. Near patient testing in general practice: attitudes of general practitioners and practice nurses, and quality assurance procedures carried out. Br J Gen Pract 1994;44:577-80.
18. Thue G, Sandberg S, Bullock DG. Comparison of the use of a dry chemistry analyser in primary care in Norway and the United Kingdom. Br J Gen Pract 1993,43:10-14.
19. Hobbs DFR, Broughton PMG, Kenkre JE, et al. Comparison of the use of four desktop analysers in six urban general practices. Br J Gen Pract 1992;42:317-21.
20. Gregory LC, Duh S-H, Christenson RH Eight compact analysis systems evaluated for measuring total cholesterol. Clin Chem 1994;40:579-85.
21. Law WT, Doshi S, McGeehan J, et al. Whole-Wood test for total cholesterol by a self-metering, self-timing disposable device with built in quality control. Clin Chem 1997;43: 384-9.
22. Anonymous. Home cholesterol testing. Lancet 1992;340: 1386.
23. Thompson SG, Pocock SJ. The variability of serum cholesterol measurements: implications for screening and monitoring, J Clin Epidemiol 1990;43:783 9.
24. Reynolds KD, Gillum JL, et al. Comparing two strategies to modify dietary behavior and serum cholesterol. J Cardiovasc Risk 1997;4:1-5.
25. Robertson I, Phillips A, Mant D, et al. Motivational effect of cholesterol measurement in general practice health checks. Br J Gen Pract 1992;42:469-72.
26. Elton PJ, Ryman A, Hammer M, et al. Randomised controlled trial in northern England of the effect of a person knowing their own serum cholesterol concentration. J Epidemiol Community Health 1994;48:22-5.
27. Haynes RB, Sackett DL, Taylor DW, et al. Increased absenteeism from work after detection and labelling of hypertensive patients. N Engl J Med 1978;299:741-4.
28. MacDonald L, Sackett DL, Haynes R, et al Labelling in hypertension: a review of the behavioural and psychological consequences J Chron Dis 1984;37:933-42
29. Brett AS. Psychologic effects of the diagnosis and treatment of hypercholesterolaemia. lessons from case studies. Am J Med 1991;91:642-7.
30. Irving MJ, Logan AG. Is knowing your cholesterol number harmful? J Clin Epidemiol 1994;47:131-45.
31. Havas S, Reisman J, Hsu L, et al. Does cholesterol screening result in negative labelling effects? Arch Intern Med 1991;151:113-9.
32. Kinlay S, Heller R. Effectiveness and hazards of case finding for a high cholesterol concentration. BMJ 1990;300:1545-7.
33. Neil HAW, Roe L, Godlee RJ, et al. Randomised controlled trial of lipid lowering advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ 1995; 310:569-73.
34. Ebrahim S, Davey Smith G. Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease. BMJ 1997;314 112-7.
35. Brunner E, White I, Thorogood M, et al. Can dietary interventions change diet and cardiovascular risk factors? A meta-analysis of randomized controlled trials Am J Public Health 1997;87.1415-22.
36. Tang JL, Armitage JM, Lancaster T, et al. Systematic review of dietary intervention trials to lower cholesterol in free-living subjects. BMJ 1998;316:1213-20.
37. Ebrahim S, Davey Smith G. Health promotion in older people for the prevention of coronary heart disease and stroke, London. Health Education Authority, 1996.
38. Neil HAW, Silagy CA, Lancaster T, et al. Garlic powder in the treatment of moderate hyperlipidaemia: a controlled trial and meta-anatysis. J R Coll Physicians Londn 1996;30: 329-34.
39. Rispin G, Keenan J, Jacobs D, et al. Oat products and lipid lowering. A meta-analysis JAMA 1992;267:3317-25.
40. Olsen BH, Anderson SM, Becker MP, et al. Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: results of a meta-analysis. J Nutrition 1997;127:1973-80.
41. Anderson J, Johnstone B, Cook-Newell M. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995;333:276-82.
42. Shepherd J, Cobbe S, Ford E, et al Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995;333:1301-7.
43. Scandinavian Simvastatin Survival Study Group. Randomized controlled trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandanavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
44. Sacks F, Pfeffer M, Move L, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335: 1001-9
45. Tonkin A. Long term intervention with pravastatin in ischaemic heart disease. Preliminary results. American Heart Association meeting, November 1997.
46. Davcy Smith G, Song FS, Sheldon T Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993;306:1367-73.
47. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615-22.
48. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandanavian simvastatin survival study (4S). Circulation 1997;96: 4211-18.
49. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy. Circulation 1995,92:2419-25.
50. Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med 1995,155:1933-41.
51. Burt A, Thomley P, Illingworth D, et al. Stopping smoking after myocardial infarction Lancet 1974;i:304-6.
52. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;ii:757-61.
53. De Longeril M, Salen P, Monjaud I, et al. The "diet heart" hypothesis in secondary prevention of coronary heart disease. Eur J Public Health 1997;18:13-8.
54. De Longeril M, Renaud S, Mamelle N, et al. Mediterranean α-linoleic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1993;343:1454-9.
55. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 1990;132:612-28.
56. Morris JN. Exercise versus heart attack: questioning the consensus? Res Q Exerc Sport 1996;87:216-20.
57. Ashenden R, Silagy C, Weller D. A systematic review of the effectivneess of promoting lifestyle change in general practice. Fam Pract 1997;14:160-75.
58. Naidoo B, Thurogood M, McPherson K, et al. Modelling the effects of increased physical activity on coronary heart disease in England and Wales. J Epidemiol Community Health 1997;51:144-50.
59. Ebrahim S, Davey Smith G Health promotion for coronary heart disease. Eur Heart J 1998 (in press).
60. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of atiplatelet therapy- I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106
61. Medical Research Council. General practice research framework. Thrombosis prevention trial: randomised trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-41.
62. Collins R, MacMahon S, Blood pressure, antihypertensive drug treatment and the risks of stroke and coronary heart disease. Br Med Bull 1994;50-272-98.
63. Insua JT, Sacks HS, Lau T-S, et al. Drug treatment of hypertension in the elderly. Ann Intern Med 1994;121 355-62.
64. Egger M, Daves Smith G, Philips AN. Meta-analysis, principles, and procedures. BMJ 1997;315-1533-7.
65. MacMahon S, Rodgers A, Neal B, et al. Blood pressure lowering for the secondary prevention of myocardial infarction and stroke. Hypertension 1997;29:537-8.
66. Caro J, Klittich W, McGuire A, et al The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997;315:1577-82.
67. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of sirnvastatin treatment to lower cholesterol levels in patients with coronary heart disease N Engl J Med 1997;336:332-6.
68. Jonsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering Results from the Scandinavian simvastatin survival study (4S). Eur Heart J 1996;17:1001-7
69. Perdersen TR, Kjekshus J, Berg K, et al Cholesterol lowering and the use of health care resources. Results from the Scandinavian simvastatin survival survey. Circulation 1996; 93.1796-802
70. Johannesson M, Borgquist L, Johsson B, et al for the CELL Study Group. The cost-effectiveness of lipid lowering in Swedish primary health care. J Intren Med 1996;240:23-9.
71. Buck D, Godfrey C, Parrott S, et al. Cost effectiveness of smoking cessation interventions. York: Centre for Health Economics, University of York and Health Education Authority, 1997.
72. Avins AL, Browner WS. Lowering risk without lowering cholesterol: implications for national cholesterol policy. Ann Intern Med 1996;125:502-6.
73. ASPIRE steering group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE: principal results Heart 1996;75:334-42.
74. Haq IU, Ramsay LE, Pickin DM, et al Lipid-lowering for the prevention of coronary heart disease: what policy now? Clin Sci (Colch) 1996;91:399-413.
75. Ramsay LE, Haq IU, Jackson PR, at al. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996;348: 387-8.
76. Vallance P, Martin J. Drug therapy for coronary heart disease the Sheffield table. Lancet 1997;350.1854.